Dinoxyline: Difference between revisions

Browse history interactively
Page 1
Page 2
← Previous edit
Content deleted Content added
VisualWikitext
CheMoBot (talk | contribs)
Bots
141,565 edits
Updating {{drugbox}} (no changed fields - added verified revid - updated 'ChemSpiderID_Ref', 'DrugBank_Ref', 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEBI_Ref') per [[WP:CHEMVALID|Chem/Drugbox validation
auto mw
 
(17 intermediate revisions by 15 users not shown)
Line 1: Line 1:
{{Short description|Chemical compound}}
{{Drugbox
{{Drugbox
| verifiedrevid = 414757924
| verifiedrevid = 449581671
| IUPAC_name = 8,9-dihydroxy-1,2,3,11b-tetrahydrochromeno[4,3,2,-de]isoquinoline
| IUPAC_name = 8,9-dihydroxy-1,2,3,11b-tetrahydrochromeno[4,3,2,-''de'']isoquinoline
| image = Dinoxyline Structure.svg
| image = Dinoxyline_structure.png

⚫
| CAS_number =
<!--Clinical data-->
⚫
| ATC_prefix = none
| ATC_suffix =
| tradename =
| PubChem = 9819126
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
⚫
| pregnancy_US = <!-- A / B / C / D / X -->
⚫
| pregnancy_category =
⚫
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
⚫
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->
⚫
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->
⚫
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
⚫
| legal_status =
⚫
| routes_of_administration =

<!--Pharmacokinetic data-->
⚫
| bioavailability =
⚫
| protein_bound =
⚫
| metabolism =
⚫
| elimination_half-life =
⚫
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|CAS}}
⚫
| CAS_number = 757176-96-8
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 9T7B8CV47A
⚫
| ATC_prefix = none
| ATC_suffix =
| PubChem = 9819126
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =
| DrugBank =
| ChemSpiderID = 7994875
⚫
| C=15 | H=13 | N=1 | O=3

| molecular_weight = 255.268
<!--Chemical data-->
⚫
| smiles = c3ccc(Oc24)c1c3CNCC1c4ccc(O)c2O
⚫
| C=15 | H=13 | N=1 | O=3
⚫
| bioavailability =
⚫
| smiles = c3ccc(Oc24)c1c3CNCC1c4ccc(O)c2O
⚫
| protein_bound =
| StdInChI = 1S/C15H13NO3/c17-11-5-4-9-10-7-16-6-8-2-1-3-12(13(8)10)19-15(9)14(11)18/h1-5,10,16-18H,6-7H2
⚫
| metabolism =
| StdInChIKey = QOHSTVKJXZTEOL-UHFFFAOYSA-N
⚫
| elimination_half-life =

⚫
| excretion =
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
⚫
| pregnancy_US = <!-- A / B / C / D / X -->
⚫
| pregnancy_category=
⚫
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
⚫
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->
⚫
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->
⚫
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
⚫
| legal_status =
⚫
| routes_of_administration =
}}
}}


'''Dinoxyline''' is a synthetic compound developed for scientific research, which acts as a potent [[full agonist]] at all five [[dopamine receptor]] subtypes.<ref name="pmid15018913">{{cite journal |author=Grubbs RA, Lewis MM, Owens-Vance C, Gay EA, Jassen AK, Mailman RB, Nichols DE |title=8,9-dihydroxy-1,2,3,11b-tetrahydrochromeno[4,3,2,-de]isoquinoline (dinoxyline), a high affinity and potent agonist at all dopamine receptor isoforms |journal=Bioorganic & Medicinal Chemistry |volume=12 |issue=6 |pages=1403–12 |year=2004 |month=March |pmid=15018913 |doi=10.1016/j.bmc.2004.01.008 |url=}}</ref><ref name="pmid15985612">{{cite journal |author=Ryman-Rasmussen JP, Nichols DE, Mailman RB |title=Differential activation of adenylate cyclase and receptor internalization by novel dopamine D1 receptor agonists |journal=Molecular Pharmacology |volume=68 |issue=4 |pages=1039–48 |year=2005 |month=October |pmid=15985612 |doi=10.1124/mol.105.012153 |url=}}</ref><ref name="pmid18642350">{{cite journal |author=Zhang J, Xiong B, Zhen X, Zhang A |title=Dopamine D1 receptor ligands: where are we now and where are we going |journal=Medicinal Research Reviews |volume=29 |issue=2 |pages=272–94 |year=2009 |month=March |pmid=18642350 |doi=10.1002/med.20130 |url=}}</ref>
'''Dinoxyline''' is a [[synthetic compound]] developed for scientific research, which acts as a potent [[full agonist]] at all five [[dopamine receptor]] subtypes.<ref name="pmid15018913">{{cite journal |vauthors=Grubbs RA, Lewis MM, Owens-Vance C, Gay EA, Jassen AK, Mailman RB, Nichols DE |title=8,9-dihydroxy-1,2,3,11b-tetrahydrochromeno[4,3,2,-''de'']isoquinoline (dinoxyline), a high affinity and potent agonist at all dopamine receptor isoforms |journal=Bioorganic & Medicinal Chemistry |volume=12 |issue=6 |pages=1403–12 |date=March 2004 |pmid=15018913 |doi=10.1016/j.bmc.2004.01.008 }}</ref><ref name="pmid15985612">{{cite journal |vauthors=Ryman-Rasmussen JP, Nichols DE, Mailman RB |title=Differential activation of adenylate cyclase and receptor internalization by novel dopamine D1 receptor agonists |journal=Molecular Pharmacology |volume=68 |issue=4 |pages=1039–48 |date=October 2005 |pmid=15985612 |doi=10.1124/mol.105.012153 |s2cid=14398107 }}</ref><ref name="pmid18642350">{{cite journal |vauthors=Zhang J, Xiong B, Zhen X, Zhang A |title=Dopamine D1 receptor ligands: where are we now and where are we going |journal=Medicinal Research Reviews |volume=29 |issue=2 |pages=272–94 |date=March 2009 |pmid=18642350 |doi=10.1002/med.20130 |s2cid=25334596 }}</ref>


== References ==
== References ==
{{Reflist}}
{{Reflist}}


{{Dopamine receptor modulators}}
{{Dopaminergics}}


[[Category:Dopamine agonists]]
[[Category:Catechols]]
[[Category:Synthetic phenolic drugs]]
[[Category:D1-receptor agonists]]
[[Category:D2-receptor agonists]]
[[Category:D3 receptor agonists]]
[[Category:D4 receptor agonists]]
[[Category:D5 receptor agonists]]




{{nervous-system-drug-stub}}
{{Nervous-system-drug-stub}}
Retrieved from "https://en.wikipedia.org/wiki/Special:ComparePages"